Kiora Pharmaceuticals (KPRX) Q3 2024 earnings summary

Executive summary

• Entered a $16M upfront strategic licensing deal for KIO-301 with Théa Open Innovation, with up to $285M in milestones and tiered royalties up to low 20% on net sales; all R&D expenses for KIO-301 reimbursed from agreement date.

• Advanced KIO-301 (retinitis pigmentosa) and KIO-104 (retinal inflammation) into Phase 2 studies, with regulatory approvals and trial designs finalized; first patient dosing for KIO-301 expected 1H 2025.

• Maintained strong liquidity with $29.0M in cash, cash equivalents, and short-term investments, plus $1.8M in collaboration receivables as of September 30, 2024.

• Partnership with Théa supports R&D for KIO-301, enabling further investment in KIO-104.

• KIO-201 development discontinued; full impairment recognized.

Financial highlights

• Reported $16M in collaboration revenue and $20K in grant revenue for the nine months ended September 30, 2024, compared to no revenue in the prior year period.

• Net income of $7.8M for the nine months ended September 30, 2024, versus a net loss of $10.2M in the prior year period.

• Net loss for Q3 2024 was $3.4M, an improvement from $5.8M in Q3 2023, mainly due to a $1.1M non-cash gain from contingent consideration.

• Operating expenses decreased to $8.9M from $10.5M year-over-year, driven by lower R&D impairment and contingent consideration adjustments.

• R&D expenses were $2.2M before $0.9M reimbursement, resulting in net R&D expenses of $1.3M (up from $1.1M in Q3 2023).

Outlook and guidance

• Sufficient cash and investments to fund planned operations into 2027, excluding potential partnership milestones.

• Additional financing will be needed for future development and commercialization beyond current plans.

• R&D expenses projected to increase as patient enrollment begins for the KLARITY trial.

• Topline results from ABACUS-2 and KLARITY trials expected to inform further development.